Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, has officially announced the launch of its “all-in-one” contract research organization (CRO), site, as well as technology offering focused on the unique needs of cardiovascular clinical trials.
To understand the significance of such a development, we must take into account how cardiovascular disease happens to be the leading death cause in both men and women, as well as most racial groups across US. As if that wasn’t bad enough, clinical trials for these conditions require large, diverse participant populations to capture variability in disease presentation and risk factors, along with extended follow-up to assess long-term outcomes and quality of life improvements.
Keeping that in mind, implementing patient-centric approaches in such studies, like remote-monitoring or decentralized trial designs, critical to reduce barriers to participation and observe how these interventions perform in the real world.
In response, Lindus Health’s latest offering introduces a specialized mechanism to equip sponsors with all the necessary resources to navigate the distinct challenges that come with conducting clinical trials across the cardiovascular space.
“Patient experience is paramount in cardiovascular studies,” said Meri Beckwith, co-founder at Lindus Health. “Our novel site services and patient engagement strategies enable us to meet patients wherever they are—on site or in their real-world environments—while producing meaningful, high-quality data for sponsors to develop cardiovascular interventions.”
Talk about the given “All-in-One Cardiovascular CRO” solution on a slightly deeper level, we begin from its promise to provide end-to-end CRO support. This translates to how Lindus Health conceives for users complete project management and operational services to aid their cardiovascular studies, managing all aspects of study design and startup responsibilities to data delivery, and everything in between.
Next up, there is an assortment of advanced recruitment capabilities. These capabilities stem from Lindus’ partnerships with cardiology practices, primary care networks, and local community organizations, and through utilizing internal tools like EHR-based screenings, and direct-to-patient campaigns. You see, leveraging the stated partnerships and tools, the company is able to efficiently recruit diverse and representative patient populations for cardiovascular research, and too, twice as fast as other CROs.
Another detail worth a mention here is rooted in the solution’s customizable eClinical technology. Here, the company’s home-grown platform, Citrus. aids trial execution, integrates critical trial tools, including CTMS, EDC, telehealth, and eConsent, so to create a unified system tailored as per the specific needs of cardiovascular studies.
Moving on to the brand of regulatory expertise this solution can bring forth, it relates to Lindus’ comprehensive knowledge about regulatory frameworks, as well as its proven tendency to keep pace with evolving trends across cardiovascular clinical research.
Finally, our last piece of highlight comes disguised as new offering’s potential in regards to providing full-spectrum solutions. Simply speaking, we can say that, no matter whether it’s single-site, multi-site, hybrid, or decentralized trial models, Lindus Health’s dedicated site operations team works closely with investigators and site staff to seamlessly execute cardiovascular studies.
Making this development all the more valuable is the company’s record so far. In case you weren’t aware, till date, Lindus Health has enrolled over 8,000 patients in cardiovascular studies across the US, UK, and EU.
“Lindus Health has been a stellar partner in our device trial,” said Jay Shah, Chief Medical Officer at Aktiia. “We’ve recruited participants faster than we could have ever anticipated, and their clinical operations team has been efficient, transparent problem-solvers every step of the way.”
